# 177Lu-PSMA-R2 in Patients With PSMA Positive Progressive, Metastatic, Castration Resistant Prostate Cancer

> **NCT03490838** · PHASE1 · TERMINATED · sponsor: **Advanced Accelerator Applications** · enrollment: 27 (actual)

## Conditions studied

- Prostatic Neoplasm

## Interventions

- **DRUG:** 177Lu-PSMA-R2

## Key facts

- **NCT ID:** NCT03490838
- **Lead sponsor:** Advanced Accelerator Applications
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-05-24
- **Primary completion:** 2021-05-26
- **Final completion:** 2022-06-02
- **Target enrollment:** 27 (ACTUAL)
- **Why stopped:** Recruitment for PROter A206T-G01-001 (NCT03490838) was halted in Phase I by sponsor decision. Phase II expansion portion of the study was never initiated.
- **Last updated:** 2025-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03490838

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03490838, "177Lu-PSMA-R2 in Patients With PSMA Positive Progressive, Metastatic, Castration Resistant Prostate Cancer". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT03490838. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*